کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2753168 | 1149618 | 2010 | 4 صفحه PDF | دانلود رایگان |
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are indicated in second-line treatment for non–small-cell lung cancer and are, in general, well tolerated. In some patients, side effects can be problematic, necessitating dose attenuation and changes in frequency of administration. A lung tumor with an EGFR mutation confers a high treatment response rate to EGFR TKIs. We present the case reports of 2 patients, both with EGFR mutations in which excellent responses were seen despite dosages and administration frequencies far below recommended levels. In addition, in the face of apparent resistance, small increases in doses overcame this. The possible factors involved in response and resistance to EGFR TKIs and issues around length of treatment are discussed.
Journal: Clinical Lung Cancer - Volume 11, Issue 5, September 2010, Pages E5–E8